News Sentiment

RARE sentiment intelligence

Ultragenyx news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 55 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 33.82 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+1.0% over one week, +38.9% over four weeks, trend active, and near fair-value range.

Latest direct headline Negative

Law firm probes Ultragenyx officers for alleged false statements on drug trial results

Market Reaction

Balanced read

59/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction 1.0% Price digesting
Trend fit Trend active 38.9% over four weeks
Fair value -10.9% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 37
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 8
TradingView 5
simplywall.st 5
www.marketscreener.com 4
GlobeNewswire 3
Moomoo 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 33
Earnings 13
Regulatory and legal 3
Analyst action 3
Deals and strategy 1
Macro sensitivity 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Pluang Direct company coverage

Law firm probes Ultragenyx officers for alleged false statements on drug trial results

Johnson Fistel, PLLP is investigating Ultragenyx Pharmaceutical's officers and directors for allegedly misleading shareholders about the effectiveness of their drug setrusumab in a Phase III trial. The firm claims Ultragenyx made false statements regarding the trial's success and

Tone
Negative 19/100
Event
Earnings
Published
15 Jul 2026 16:12
Source
Pluang
GlobeNewswire Direct company coverage

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE)

Johnson Fistel, PLLP is investigating potential claims on behalf of long-term shareholders of Ultragenyx Pharmaceutical Inc. (RARE) for alleged breaches of fiduciary duty by its officers and directors. The investigation stems from a securities class action complaint alleging that

Tone
Negative 18/100
Event
Regulatory and legal
Published
15 Jul 2026 15:11
Source
GlobeNewswire
Sahm Direct company coverage

Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value Benchmarks - Has The Bull Case Changed?

Ultragenyx Pharmaceutical (RARE) was reclassified within the Russell index family, moving from larger-cap indices to the Russell 2000 and related growth/value benchmarks. This migration affects trading flows and investor perception, though it doesn't change the company's fundamen

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 22:10
Source
Sahm
GlobeNewswire Direct company coverage

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

Ultragenyx Pharmaceutical Inc. released its 2025 Impact Report, highlighting its dedication to patients with rare diseases, innovation in therapy development, and global impact. The report covers progress across six key pillars: Innovation, Patients, People, Communities, Planet,

Tone
Positive 73/100
Event
Market update
Published
09 Jul 2026 09:40
Source
GlobeNewswire
Investing.com Direct company coverage

Ultragenyx releases 2025 impact report on rare disease work

Ultragenyx Pharmaceutical Inc. published its 2025 Impact Report, detailing its work on rare and ultra-rare disease treatments, including advancing five investigational therapies and investing 62% of operating expenses in R&D. Despite unprofitability, the company saw a 55% year-to

Tone
Positive 61/100
Event
Regulatory and legal
Published
08 Jul 2026 14:11
Source
Investing.com
Stock Titan Direct company coverage

Ultragenyx says five rare-disease programs reached pivotal trials in 2025

Ultragenyx (NASDAQ: RARE) released its 2025 Impact Report, detailing significant progress in developing therapies for rare and ultra-rare diseases. The report highlights that five investigational therapies advanced into pivotal clinical programs, and the company supported over 70

Tone
Positive 76/100
Event
Regulatory and legal
Published
08 Jul 2026 13:11
Source
Stock Titan
Investing.com Direct company coverage

Ultragenyx CFO Howard Horn sells $155,644 in company shares

Ultragenyx Pharmaceutical Inc.'s CFO, Howard Horn, sold 4,698 shares of company stock for a total of $155,644 on July 1, 2026. This transaction was executed under a Rule 10b5-1 trading plan, leaving him with 100,991 directly held shares. The company's stock has seen significant g

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 19:40
Source
Investing.com
Stock Titan Direct company coverage

Ultragenyx (RARE) CFO sells 4,698 shares, retains 100,991 stake

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, sold 4,698 shares of common stock at $33.13 per share in an open-market transaction. Following this sale, Horn directly owns 100,991 shares, which includes RSUs subject to vesting. The transaction was made pur

Tone
Negative 35/100
Event
Deals and strategy
Published
06 Jul 2026 19:40
Source
Stock Titan
富途牛牛 Direct company coverage

Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Shift From Loss To Profit

This article focuses on Ultragenyx Pharmaceutical Inc.'s financial performance, particularly its recent shift from reporting a loss to anticipated profitability. It highlights analyst expectations and key financial metrics, suggesting a positive outlook for the company's future e

Tone
Positive 77/100
Event
Earnings
Published
05 Jul 2026 19:40
Source
富途牛牛
Investing.com Canada Direct company coverage

Form 144 ULTRAGENYX PHARMACEUTICAL INC. For: 1 July By Investing.com

This article announces that a Form 144 filling for Ultragenyx Pharmaceutical Inc. was made on July 1st. The brief notice provides the stock symbol RARE, which experienced a -3.02% change, and includes a link to view comments. The content is primarily a filing announcement with as

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 05:39
Source
Investing.com Canada
Stock Titan Direct company coverage

RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards

An affiliate of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has filed a Form 144, detailing proposed and recent sales of Common Stock and scheduled issuances of Restricted Stock and Performance Shares. The filing indicates open-market sales by Howard Horn totaling over 9,300 sh

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:39
Source
Stock Titan
Finviz Direct company coverage

RARE - Ultragenyx Pharmaceutical Inc Latest SEC Filings

This article provides a detailed financial overview and snapshot of Ultragenyx Pharmaceutical Inc (RARE), including its market performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's recent stock close, per

Tone
Negative 40/100
Event
Analyst action
Published
01 Jul 2026 16:39
Source
Finviz
www.marketscreener.com Direct company coverage

Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Growth Benchmark

Ultragenyx Pharmaceutical Inc. (RARE) has been removed from the Russell 1000 Growth Benchmark. This news comes alongside several other index adjustments for the company, including additions to various Russell 2000 and 3000 benchmarks, and drops from other Russell 1000 and Midcap

Tone
Negative 38/100
Event
Market update
Published
30 Jun 2026 05:39
Source
www.marketscreener.com
Market source Direct company coverage

Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?

Ultragenyx (RARE) shares recently rallied 5.2% due to investor optimism over its growing portfolio of rare disease therapies and a promising late-stage pipeline. Key drivers include products like Crysvita, Dojolvi, and Mepsevii, along with upcoming FDA decisions and clinical tria

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 05:09
Source
Market source
Simply Wall Street Direct company coverage

Does Ultragenyx (RARE) Shifting Into Small‑Cap Value Indices Recast Its Rare‑Disease Growth Story?

Ultragenyx Pharmaceutical Inc. (RARE) has been reclassified into Russell small-cap and value indices, including the Russell 2000. While this shift impacts its investor base and index-linked demand, the article emphasizes that the core investment narrative remains tied to upcoming

Tone
Neutral 50/100
Event
Macro sensitivity
Published
30 Jun 2026 02:40
Source
Simply Wall Street
www.marketscreener.com Direct company coverage

Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Value Benchmark

Ultragenyx Pharmaceutical Inc. (NasdaqGS: RARE) has been added to the Russell 2000 Value Benchmark. This news comes after several recent changes in its index inclusions, including being added to the Russell 2000 Growth Benchmark and being dropped from various Russell 1000 and Mid

Tone
Positive 64/100
Event
Market update
Published
29 Jun 2026 11:06
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell Small Cap Comp Value Benchmark

Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) has been added to the Russell Small Cap Comp Value Benchmark. The biopharmaceutical company focuses on developing and commercializing treatments for rare genetic diseases, with a pipeline including products like Crysvita, Mepsevii, D

Tone
Positive 75/100
Event
Market update
Published
29 Jun 2026 06:09
Source
marketscreener.com
TradingView Direct company coverage

Enterprise value to EBIT forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE

The article focuses on the enterprise value to EBIT forward metric for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). It provides a snapshot of the company's financial data as part of a trading platform's market analysis. The content is primarily a data placeholder within a finan

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 05:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE

This article provides financial information for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), specifically focusing on its "Price to book forward" metric. The content appears to be a financial data snippet from TradingView, including market information and an overview of the com

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 01:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE

This article provides financial information for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), specifically focusing on its price to sales forward metric. The content appears to be a financial data page from TradingView, displaying the current market status and available data cat

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 23:09
Source
TradingView
www.marketscreener.com Direct company coverage

Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Dynamic Index

Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) has been removed from the Russell 1000 Dynamic Index, as announced on June 28, 2026. This news comes alongside similar announcements of its removal from the Russell Midcap Index and Russell 1000 Index on the same day. The company is

Tone
Negative 28/100
Event
Market update
Published
28 Jun 2026 21:07
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) dropped from Russell 1000 Index

Ultragenyx Pharmaceutical Inc. (RARE) has been removed from the Russell 1000 Index. This news follows a recent report of the company's Q1 loss widening and revenue falling, despite reaffirmed earnings guidance for 2026 and initial guidance for 2027. Ultragenyx focuses on developi

Tone
Negative 37/100
Event
Earnings
Published
28 Jun 2026 21:03
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to revenue forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE

This article focuses on the enterprise value to revenue forward metric for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). It provides financial and stock market information within the TradingView platform context. The content appears to be a stub or a section of a larger financia

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 09:09
Source
TradingView